eMedicine Specialties > Physical Medicine and Rehabilitation > Disorders of the Motor Unit

Kugelberg Welander Spinal Muscular Atrophy: Treatment & Medication

Author: Joyce L Oleszek, MD, Assistant Professor, Department of Physical Medicine and Rehabilitation, University of Colorado at Denver Health Sciences Center, The Children's Hospital of Denver
Coauthor(s): Stephanie E Vallee, MS, Certified Genetic Counselor, Dartmouth-Hitchcock Medical Center, Children's Hospital at Dartmouth; Michael Dichiaro, MD, Chief Resident, Department of Physical Medicine and Rehabilitation, University of Colorado at Denver Health Sciences Center; Mary Louise Caire, MD, Consulting Staff, Department of Physical Medicine and Rehabilitation, Wise Regional Medical Center; Stephen Kishner, MD, Residency Program Director, Professor of Clinical Medicine, Department of Medicine, Section of Physical Medicine and Rehabilitation, Louisiana State University School of Medicine
Contributor Information and Disclosures

Updated: Jul 29, 2008

Treatment

Rehabilitation Program

Physical Therapy

Spinal muscular atrophy (SMA) has no known cure; thus, most care for the patient with SMA is focused on symptomatic control and preventative rehabilitation.14 Maintaining the patient's joint mobility is very important, because the goal is to decrease the incidence of contractures. Plantar flexion contractures are the most common.

Ankle-foot orthotics worn at night may help to provide prolonged, passive stretching to prevent worsening of ankle plantar flexion contractures.

Stretching and strength training in patients under the care of an experienced physical therapist are very important components of the preventative rehabilitation approach. For school-age patients, a physical therapist can provide consultation regarding appropriate or adaptive physical education activities.

Aquatic therapy is an excellent way to maintain mobility, strength, and flexibility.

Because of the progressive weakness associated with SMA, patients may require the full-time use of a wheelchair. For these patients, there are multiple assistive devices available that enable them to maintain a level of independence. Patients are encouraged to use manual wheelchairs rather than electric ones, when possible, to maintain cardiovascular fitness and upper body strength.

Occupational Therapy

The occupational therapist plays an essential role in addressing the individual needs of patients with spinal muscular atrophy. Occupational therapy is useful for teaching the patient ways to increase his/her independence in activities of daily living (ADL). Fine motor skills may be affected by fatigue. Affected school-age patients may benefit from an occupational therapy consultation that addresses keyboarding and other ways to avoid fatigue from upper extremity activities in the classroom.

Patients may eventually require the use of a wheelchair on a full-time basis. In addition, multiple assistive devices are available that enable patients to maintain a higher level of independence.

Speech Therapy

Patients with spinal muscular atrophy may require consultation with a speech therapist if dysphagia is present or diet modification is needed.

Medical Issues/Complications

  • Orthopedic15 - A few studies have shown that scoliosis is a major problem in half of the patients with spinal muscular atrophy (SMA) type III. However, scoliosis occurs less frequently in patients with SMA type III than it does in persons with type II, and it is not as severe. Routine radiography should be performed, and the patient may require a thoracolumbar sacral orthosis (TLSO) or may need surgery. Spinal orthoses have been shown to assist in containing the spinal deformity until instrumentation and fusion can be performed, if necessary.

    Hip subluxation is also common. One author reports 50% of patients with SMA type III have hip subluxation or dislocation, with rare improvement in function from surgical reduction.
  • Respiratory - Pulmonary disease is the major cause of morbidity and mortality in patients with SMA types I and II and in a small portion of persons with SMA type III.6,7,8 The presence of expiratory muscle weakness that is greater than inspiratory muscle weakness, with relative sparing of the diaphragm, leads to impaired cough, hypoventilation during sleep, chest wall underdevelopment, and the potential for recurrent infections. One author found that in SMA type III, pulmonary function was preserved until age 13 years, and that by age 17 years, pulmonary function decreased to 79%.

    Pulmonary function tests can be performed, with forced vital capacity (FVC) as the best predictor of respiratory reserve; these tests should be done on a regular basis. Treatments may include noninvasive ventilation, including intermittent positive pressure ventilation, bilevel positive airway pressure ventilation, and negative pressure ventilation. Infections should be treated aggressively with antibiotics, mucolytics and bronchodilators, oxygen, chest PT and postural drainage, and a cough-assist machine.
  • Sleep disorders - Questions regarding sleep hygiene and fatigue should be addressed. Patients with SMA type III frequently report fatigue. One case report described a 46-year-old man with SMA type III whose increasing daytime fatigue caused by nocturnal snoring and apnea resolved with nighttime use of continuous positive airway pressure with a nasal mask.16 Another case report documented the coexistence of sleep-disordered breathing and dilated cardiomyopathy in a 53-year-old patient with SMA type III.17 Similarly, symptoms were virtually eliminated with nighttime use of continuous positive airway pressure via nasal mask. Sleep studies can be used to screen for nocturnal hypoventilation.
  • Contractures - Contractures are usually mild as long as patients remain ambulatory.
  • Dysphagia

Surgical Intervention

  • If scoliosis develops in a patient with spinal muscular atrophy, spinal instrumentation and fusion may be necessary.18 Some upper extremity function can be lost after fusion.
  • Tendon lengthenings may be needed to improve joint position.

Consultations

  • Genetic counseling for spinal muscular atrophy (SMA) - Parents, patients, and extended family members may benefit from genetic counseling. Carrier detection relies on determining the number of exon 7 – containing SMN1 gene copies present in an individual. SMA carrier testing, a polymerase chain reaction – based dosage assay, is available on a limited clinical basis. For a number of reasons, test results can be difficult to interpret and should be provided in the context of formal genetic counseling.
  • Vocational rehabilitation counseling - This type of counseling may be beneficial to facilitate the transition from secondary school to postsecondary education or for vocational planning.

Medication

Numerous treatment trials for spinal muscular atrophy (SMA) have been described or are currently underway.19 Medications being studied for upregulation of SMN2 protein production or for increase of exon 7 inclusion include phenylbutyrate, valproic acid, suberoylanilide hydroxamic acid, and hydroxyurea. The neuroprotective medications being investigated, including gabapentin and riluzole, are thought to provide protection from oxidative stress. Albuterol has been studied for its trophic/anabolic effects. Exercise therapy in rats has shown modest improvement in survival and modest decrease in motor neuron loss. Treatment with stem cells is also an area undergoing further study.

A single study from the Russian literature in 1980 suggested that lithium may have a role in slowing the disease progression, but this has not been corroborated. Further studies are needed to investigate this.20

A study using thyrotropin-releasing hormone as a treatment for SMA types II and III in children showed promising results. More studies are warranted to further investigate this possible treatment.21

Merlini and colleagues performed a multicenter, randomized, controlled trial of gabapentin versus no treatment in 120 patients with SMA type II or III for 12 months.22 A significant improvement in lower extremity, maximum, voluntary isometric contraction was seen.

More on Kugelberg Welander Spinal Muscular Atrophy

Overview: Kugelberg Welander Spinal Muscular Atrophy
Differential Diagnoses & Workup: Kugelberg Welander Spinal Muscular Atrophy
Treatment & Medication: Kugelberg Welander Spinal Muscular Atrophy
Follow-up: Kugelberg Welander Spinal Muscular Atrophy
References

References

  1. Bradley WG, ed. Neurology in Clinical Practice. 5th ed. Philadelphia, Pa: Butterworth-Heinemann/Elsevier; 2008.

  2. Herring JA, ed. Tachdjian's Pediatric Orthopaedics. 4th ed. Philadelphia, Pa: Saunders/Elsevier; 2008.

  3. Wang CH, Finkel RS, Bertini ES, et al. Consensus statement for standard of care in spinal muscular atrophy. J Child Neurol. Aug 2007;22(8):1027-49. [Medline].

  4. Russman BS, Buncher CR, White M, et al. Function changes in spinal muscular atrophy II and III. The DCN/SMA Group. Neurology. Oct 1996;47(4):973-6. [Medline].

  5. Zerres K, Rudnik-Schöneborn S, Forrest E, et al. A collaborative study on the natural history of childhood and juvenile onset proximal spinal muscular atrophy (type II and III SMA): 569 patients. J Neurol Sci. Feb 27 1997;146(1):67-72. [Medline].

  6. Ioos C, Leclair-Richard D, Mrad S, et al. Respiratory capacity course in patients with infantile spinal muscular atrophy. Chest. Sep 2004;126(3):831-7. [Medline][Full Text].

  7. Lin LC, Jong YJ. Pulmonary function assessment in patients with spinal muscular atrophy type II and type III. Acta Paediatr Taiwan. Jan-Feb 2004;45(1):15-8. [Medline].

  8. Muscular Dystrophy Campaign sponsored workshop: recommendation for respiratory care of children with SMA type II and III. Neuromuscular Disord. 2003;13:184-189.

  9. Moosa A, Dubowitz V. Spinal muscular atrophy in childhood. Two clues to clinical diagnosis. Arch Dis Child. May 1973;48(5):386-8. [Medline][Full Text].

  10. Simic G. Pathogenesis of proximal autosomal recessive spinal muscular atrophy. Acta Neuropathol. Jul 16 2008;[Medline].

  11. Mattis VB, Bowerman M, Kothary R, et al. A SMNDelta7 read-through product confers functionality to the SMNDelta7 protein. Neurosci Lett. Jun 26 2008;[Medline].

  12. Ogino S, Wilson RB. Genetic testing and risk assessment for spinal muscular atrophy (SMA). Hum Genet. Dec 2002;111(6):477-500. [Medline].

  13. Wang CC, Chang JG, Ferrance J, et al. Quantification of SMN1 and SMN2 genes by capillary electrophoresis for diagnosis of spinal muscular atrophy. Electrophoresis. Jul 2008;29(13):2904-11. [Medline].

  14. Umphred DA, ed. Neurological Rehabilitation. 5th ed. St Louis, Mo: Mosby Elsevier; 2007.

  15. Rodillo E, Marini ML, Heckmatt JZ, et al. Scoliosis in spinal muscular atrophy: review of 63 cases. J Child Neurol. Apr 1989;4(2):118-23. [Medline].

  16. Puruckherr M, Mehta JB, Girish MR, et al. Severe obstructive sleep apnea in a patient with spinal muscle atrophy. Chest. Nov 2004;126(5):1705-7. [Medline][Full Text].

  17. Yasuma F, Kuru S, Konagaya M. Dilated cardiomyopathy in Kugelberg-Welander disease: coexisting sleep disordered breathing and its treatment with continuous positive airway pressure. Intern Med. Oct 2004;43(10):951-4. [Medline][Full Text].

  18. Merlini L, Granata C, Bonfiglioli S, et al. Scoliosis in spinal muscular atrophy: natural history and management. Dev Med Child Neurol. Aug 1989;31(4):501-8. [Medline].

  19. Swoboda KJ, Kissel JT, Crawford TO, et al. Perspectives on clinical trials in spinal muscular atrophy. J Child Neurol. Aug 2007;22(8):957-66. [Medline].

  20. Il'ina NA, Antipova RI, Khokhlov AP. [Use of lithium carbonate to treat Kugelberg--Welander spinal amyotrophy]. Zh Nevropatol Psikhiatr Im S S Korsakova. 1980;80(11):1657-60. [Medline].

  21. Tzeng AC, Cheng J, Fryczynski H, et al. A study of thyrotropin-releasing hormone for the treatment of spinal muscular atrophy: a preliminary report. Am J Phys Med Rehabil. Sep-Oct 2000;79(5):435-40. [Medline].

  22. Merlini L, Solari A, Vita G, et al. Role of gabapentin in spinal muscular atrophy: results of a multicenter, randomized Italian study. J Child Neurol. Aug 2003;18(8):537-41. [Medline].

  23. de Groot IJ, de Witte LP. Physical complaints in ageing persons with spinal muscular atrophy. J Rehabil Med. Jul 2005;37(4):258-62. [Medline].

  24. Liveson JA. Peripheral Neurology: Case Studies in Electrodiagnosis. 2nd ed. Philadelphia, Pa: FA Davis; 1991.

  25. Menkes JH. Textbook of Child Neurology. 5th ed. Baltimore, Md: Williams & Wilkins; 1995.

  26. Swaiman KF, Ashwal S, Ferriero DM, eds. Pediatric Neurology: Principles and Practice. 4th ed. Philadelphia, Pa: Mosby; 2006.

  27. Ropper AH, Brown RH. Adams and Victor's Principles of Neurology. 8th ed. New York, NY: McGraw-Hill Medical; 2005.

  28. Younger DS, Gordon PH. Diagnosis in neuromuscular diseases. Neurol Clin. Feb 1 1996;14:135-68.

  29. Zeinos M, Sampath J, Cole C, et al. Operative treatment for hip subluxations in spinal muscular atrophy. J Bone Joint Surg. 2005;87-B:1541-4.

Further Reading

Keywords

Kugelberg Welander spinal muscular atrophy, Kugelberg-Welander spinal muscular atrophy, Kugelberg Welander disease, Kugelberg-Welander disease, Wohlfart-Kugelberg-Welander syndrome, Wohlfart-Kugelberg-Welander disease, mild spinal muscular atrophy, spinal muscular atrophy, SMA, juvenile types III and IV spinal muscular atrophy, adult-onset spinal muscular atrophy

Contributor Information and Disclosures

Author

Joyce L Oleszek, MD, Assistant Professor, Department of Physical Medicine and Rehabilitation, University of Colorado at Denver Health Sciences Center, The Children's Hospital of Denver
Joyce L Oleszek, MD is a member of the following medical societies: American Academy of Physical Medicine and Rehabilitation
Disclosure: Nothing to disclose.

Coauthor(s)

Stephanie E Vallee, MS, Certified Genetic Counselor, Dartmouth-Hitchcock Medical Center, Children's Hospital at Dartmouth
Disclosure: Nothing to disclose.

Michael Dichiaro, MD, Chief Resident, Department of Physical Medicine and Rehabilitation, University of Colorado at Denver Health Sciences Center
Disclosure: Nothing to disclose.

Mary Louise Caire, MD, Consulting Staff, Department of Physical Medicine and Rehabilitation, Wise Regional Medical Center
Mary Louise Caire, MD is a member of the following medical societies: American Academy of Physical Medicine and Rehabilitation, American Medical Association, and Texas Medical Association
Disclosure: Nothing to disclose.

Stephen Kishner, MD, Residency Program Director, Professor of Clinical Medicine, Department of Medicine, Section of Physical Medicine and Rehabilitation, Louisiana State University School of Medicine
Stephen Kishner, MD is a member of the following medical societies: American Academy of Physical Medicine and Rehabilitation and American Association of Neuromuscular and Electrodiagnostic Medicine
Disclosure: Nothing to disclose.

Medical Editor

Teresa L Massagli, MD, Residency Director, Professor, Department of Rehabilitation Medicine and Pediatrics, University of Washington School of Medicine
Teresa L Massagli, MD is a member of the following medical societies: American Academy of Pediatrics, American Academy of Physical Medicine and Rehabilitation, and Association of Academic Physiatrists
Disclosure: Nothing to disclose.

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: Nothing to disclose.

Managing Editor

Kat Kolaski, MD, Assistant Professor, Departments of Orthopedic Surgery and Pediatrics, Wake Forest University School of Medicine
Kat Kolaski, MD is a member of the following medical societies: American Academy for Cerebral Palsy and Developmental Medicine and American Academy of Physical Medicine and Rehabilitation
Disclosure: Nothing to disclose.

CME Editor

Kelly L Allen, MD, Consulting Staff, Department of Physical Medicine and Rehabilitation, Lourdes Regional Rehabilitation Center, Our Lady of Lourdes Medical Center
Disclosure: Nothing to disclose.

Chief Editor

Denise I Campagnolo, MD, MS, Director of Multiple Sclerosis Clinical Research and Staff Physiatrist, Barrow Neurology Clinics, St. Joseph's Hospital and Medical Center; Investigator for Barrow Neurology Clinics; Director, NARCOMS Project for Consort
Denise I Campagnolo, MD, MS is a member of the following medical societies: Alpha Omega Alpha, American Association of Neuromuscular and Electrodiagnostic Medicine, American Paraplegia Society, Association of Academic Physiatrists, and Consortium of Multiple Sclerosis Centers
Disclosure: Teva Neuroscience Honoraria Speaking and teaching; Serono-Pfizer Honoraria Speaking and teaching

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.